Gupta Sapna, Tandon V R, Kapoor B, Gupta A, Gupta G D, Khajuria V
Post Graduate Department of Pharmacology and Therapeutics, Government Medical College, Jammu (J&K) India 180001.
J Assoc Physicians India. 2006 Mar;54:183-6.
To evaluate the effects of tamoxifen therapy on plasma lipid profile in patients of breast cancer.
A total of 55 postoperative patients of breast cancer were given tablet tamoxifen 20mg orally daily for 6 months. Estimation of plasma lipid by standard method was carried out in both pre-menopausal and postmenopausal new patients of early stage breast cancer at 0 day, 3rd month and 6th months of therapy.
Suggested that in pre-menopausal and postmenopausal patient's TC and LDL-c levels were reduced significantly, whereas, TG, VLDL-c and HDL-c were not altered. Comparison of the effects of tamoxifen in pre-menopausal and postmenopausal patients on lipid profile revealed that fall in TC and LDL-c was significantly higher at both 3 and 6 months in postmenopausal patients.
The study demonstrates that tamoxifen to favorably alter the markers of cardiovascular risk in both pre-menopausal and postmenopausal patients of breast cancer.
评估他莫昔芬治疗对乳腺癌患者血脂谱的影响。
总共55例乳腺癌术后患者每天口服20毫克他莫昔芬片，持续6个月。采用标准方法在治疗的第0天、第3个月和第6个月对早期乳腺癌绝经前和绝经后新患者的血脂进行评估。
提示绝经前和绝经后患者的总胆固醇（TC）和低密度脂蛋白胆固醇（LDL-c）水平显著降低，而甘油三酯（TG）、极低密度脂蛋白胆固醇（VLDL-c）和高密度脂蛋白胆固醇（HDL-c）未改变。比较他莫昔芬对绝经前和绝经后患者血脂谱的影响发现，绝经后患者在第3个月和第6个月时TC和LDL-c的下降幅度明显更大。
该研究表明，他莫昔芬可有效改变乳腺癌绝经前和绝经后患者心血管风险标志物。
